Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-06952229 in advanced solid tumors and prostate cancer
NCT03685591Phase 1Terminated
- Sponsor
- Pfizer
- Start
- Oct 2018
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of PF-06952229 in solid tumor and prostate cancer (PCa) (15 arms), sponsored by Pfizer. Primary endpoints: Dose-Limiting Toxicities at 28 days, Treatment-Emergent Adverse Events and 1 more. Started Oct 2018; status: terminated.
02
Drugs
PF-06952229
03
Conditions
solid tumorprostate cancer (PCa)
Beyond the preview
Go deeper on NCT03685591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03685591.